将系统性硬化症相关间质性肺病（SSc-ILD）药物分类为免疫抑制药物或抗纤维化药物是否具有误导性？ - Suppr

Suppr

超能文献

Is classifying SSc-ILD drugs as either immunosuppressive or anti-fibrotic misleading?

作者信息

Andréasson Kristofer, Hamberg Viggo, Wigén Jenny, Westergren-Thorsson Gunilla

机构信息

Section of Rheumatology, Department of Clinical Sciences, Lund University, Lund, Sweden.

Lung Biology Unit, Department of Experimental Medical Science, Lund University, Lund, Sweden.

出版信息

Nat Rev Rheumatol. 2023 Oct;19(10):675. doi: 10.1038/s41584-023-01013-4.

DOI:10.1038/s41584-023-01013-4

PMID:37605003

Abstract

摘要

相似文献

Is classifying SSc-ILD drugs as either immunosuppressive or anti-fibrotic misleading?

Nat Rev Rheumatol. 2023 Oct;19(10):675. doi: 10.1038/s41584-023-01013-4.

Reply to: Is classifying SSc-ILD drugs as either immunosuppressive or anti-fibrotic misleading?

Nat Rev Rheumatol. 2023 Oct;19(10):676. doi: 10.1038/s41584-023-01014-3.

Interstitial Lung Disease: How Should Therapeutics Be Implemented?

Rheum Dis Clin North Am. 2023 May;49(2):279-293. doi: 10.1016/j.rdc.2023.01.005.

Nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease.

Expert Rev Clin Immunol. 2020 Jun;16(6):547-560. doi: 10.1080/1744666X.2020.1777857. Epub 2020 Jun 17.

Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group.

Arthritis Res Ther. 2018 Jan 30;20(1):17. doi: 10.1186/s13075-018-1517-z.

[Interstitial lung disease in systemic sclerosis].

Rev Mal Respir. 2007 Oct;24(8):1035-46. doi: 10.1016/s0761-8425(07)92767-9.

Longitudinal Changes in Quantitative Interstitial Lung Disease on Computed Tomography after Immunosuppression in the Scleroderma Lung Study II.

Ann Am Thorac Soc. 2018 Nov;15(11):1286-1295. doi: 10.1513/AnnalsATS.201802-079OC.

Association between immunosuppressive therapy and course of mild interstitial lung disease in systemic sclerosis.

Rheumatology (Oxford). 2020 May 1;59(5):1108-1117. doi: 10.1093/rheumatology/kez407.

Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease.

Arthritis Rheumatol. 2021 Feb;73(2):295-304. doi: 10.1002/art.41512. Epub 2020 Dec 29.

Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease.

J Dermatol. 2019 Nov;46(11):1006-1013. doi: 10.1111/1346-8138.15079. Epub 2019 Sep 9.

引用本文的文献

Reply to: Is classifying SSc-ILD drugs as either immunosuppressive or anti-fibrotic misleading?

Nat Rev Rheumatol. 2023 Oct;19(10):676. doi: 10.1038/s41584-023-01014-3.

本文引用的文献

State-of-the-art evidence in the treatment of systemic sclerosis.

Nat Rev Rheumatol. 2023 Apr;19(4):212-226. doi: 10.1038/s41584-023-00909-5. Epub 2023 Feb 27.

Glycosaminoglycans: A Link Between Development and Regeneration in the Lung.

Stem Cells Dev. 2019 Jul 1;28(13):823-832. doi: 10.1089/scd.2019.0009. Epub 2019 Jun 11.

Anti-fibrotic effect of mycophenolate mofetil on Peyronie's disease experimentally induced with TGF-β.

Int J Impot Res. 2020 Mar;32(2):201-206. doi: 10.1038/s41443-019-0138-7. Epub 2019 Apr 18.

Effectiveness and safety of mycophenolate mofetil in idiopathic pulmonary fibrosis.

PLoS One. 2017 Apr 25;12(4):e0176312. doi: 10.1371/journal.pone.0176312. eCollection 2017.

Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis.

J Pharmacol Exp Ther. 2014 May;349(2):209-20. doi: 10.1124/jpet.113.208223. Epub 2014 Feb 20.

Extracellular matrix alterations and acute inflammation; developing in parallel during early induction of pulmonary fibrosis.

Lab Invest. 2012 Jun;92(6):917-25. doi: 10.1038/labinvest.2012.57. Epub 2012 Apr 2.

BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.

Cancer Res. 2008 Jun 15;68(12):4774-82. doi: 10.1158/0008-5472.CAN-07-6307.

Mycophenolate mofetil is associated with altered expression of chronic renal transplant histology.

Am J Transplant. 2007 Feb;7(2):366-76. doi: 10.1111/j.1600-6143.2006.01633.x.

In vitro evidence for a direct antifibrotic role of the immunosuppressive drug mycophenolate mofetil.

J Pharmacol Exp Ther. 2007 May;321(2):583-9. doi: 10.1124/jpet.106.117051. Epub 2007 Feb 1.

Antifibrotic actions of mycophenolic acid.

Clin Transplant. 2006;20 Suppl 17:25-9. doi: 10.1111/j.1399-0012.2006.00597.x.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Is classifying SSc-ILD drugs as either immunosuppressive or anti-fibrotic misleading?

作者信息

Andréasson Kristofer, Hamberg Viggo, Wigén Jenny, Westergren-Thorsson Gunilla

机构信息

Section of Rheumatology, Department of Clinical Sciences, Lund University, Lund, Sweden.

Lung Biology Unit, Department of Experimental Medical Science, Lund University, Lund, Sweden.

出版信息

Nat Rev Rheumatol. 2023 Oct;19(10):675. doi: 10.1038/s41584-023-01013-4.

DOI:10.1038/s41584-023-01013-4

PMID:37605003

Abstract

摘要

相似文献

Is classifying SSc-ILD drugs as either immunosuppressive or anti-fibrotic misleading?

Nat Rev Rheumatol. 2023 Oct;19(10):675. doi: 10.1038/s41584-023-01013-4.

Reply to: Is classifying SSc-ILD drugs as either immunosuppressive or anti-fibrotic misleading?

Nat Rev Rheumatol. 2023 Oct;19(10):676. doi: 10.1038/s41584-023-01014-3.

Interstitial Lung Disease: How Should Therapeutics Be Implemented?

Rheum Dis Clin North Am. 2023 May;49(2):279-293. doi: 10.1016/j.rdc.2023.01.005.

Nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease.

Expert Rev Clin Immunol. 2020 Jun;16(6):547-560. doi: 10.1080/1744666X.2020.1777857. Epub 2020 Jun 17.

Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group.

Arthritis Res Ther. 2018 Jan 30;20(1):17. doi: 10.1186/s13075-018-1517-z.

[Interstitial lung disease in systemic sclerosis].

Rev Mal Respir. 2007 Oct;24(8):1035-46. doi: 10.1016/s0761-8425(07)92767-9.

Longitudinal Changes in Quantitative Interstitial Lung Disease on Computed Tomography after Immunosuppression in the Scleroderma Lung Study II.

Ann Am Thorac Soc. 2018 Nov;15(11):1286-1295. doi: 10.1513/AnnalsATS.201802-079OC.

Association between immunosuppressive therapy and course of mild interstitial lung disease in systemic sclerosis.

Rheumatology (Oxford). 2020 May 1;59(5):1108-1117. doi: 10.1093/rheumatology/kez407.

Arthritis Rheumatol. 2021 Feb;73(2):295-304. doi: 10.1002/art.41512. Epub 2020 Dec 29.

Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease.

J Dermatol. 2019 Nov;46(11):1006-1013. doi: 10.1111/1346-8138.15079. Epub 2019 Sep 9.

引用本文的文献

Reply to: Is classifying SSc-ILD drugs as either immunosuppressive or anti-fibrotic misleading?

Nat Rev Rheumatol. 2023 Oct;19(10):676. doi: 10.1038/s41584-023-01014-3.

本文引用的文献

State-of-the-art evidence in the treatment of systemic sclerosis.

Nat Rev Rheumatol. 2023 Apr;19(4):212-226. doi: 10.1038/s41584-023-00909-5. Epub 2023 Feb 27.

Glycosaminoglycans: A Link Between Development and Regeneration in the Lung.

Stem Cells Dev. 2019 Jul 1;28(13):823-832. doi: 10.1089/scd.2019.0009. Epub 2019 Jun 11.

Anti-fibrotic effect of mycophenolate mofetil on Peyronie's disease experimentally induced with TGF-β.

Int J Impot Res. 2020 Mar;32(2):201-206. doi: 10.1038/s41443-019-0138-7. Epub 2019 Apr 18.

Effectiveness and safety of mycophenolate mofetil in idiopathic pulmonary fibrosis.

PLoS One. 2017 Apr 25;12(4):e0176312. doi: 10.1371/journal.pone.0176312. eCollection 2017.

Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis.

J Pharmacol Exp Ther. 2014 May;349(2):209-20. doi: 10.1124/jpet.113.208223. Epub 2014 Feb 20.

Extracellular matrix alterations and acute inflammation; developing in parallel during early induction of pulmonary fibrosis.

Lab Invest. 2012 Jun;92(6):917-25. doi: 10.1038/labinvest.2012.57. Epub 2012 Apr 2.

BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.

Cancer Res. 2008 Jun 15;68(12):4774-82. doi: 10.1158/0008-5472.CAN-07-6307.

Mycophenolate mofetil is associated with altered expression of chronic renal transplant histology.

Am J Transplant. 2007 Feb;7(2):366-76. doi: 10.1111/j.1600-6143.2006.01633.x.

In vitro evidence for a direct antifibrotic role of the immunosuppressive drug mycophenolate mofetil.

J Pharmacol Exp Ther. 2007 May;321(2):583-9. doi: 10.1124/jpet.106.117051. Epub 2007 Feb 1.

Antifibrotic actions of mycophenolic acid.

Clin Transplant. 2006;20 Suppl 17:25-9. doi: 10.1111/j.1399-0012.2006.00597.x.